Growth Inhibition of Re-Challenge B16 Melanoma Transplant by Conjugates of Melanogenesis Substrate and Magnetite Nanoparticles as the Basis for Developing Melanoma-Targeted Chemo-Thermo-Immunotherapy
Time schedule and results for tumor volumes, survival periods, and rates of mice treated by Protocol number 2. (a) Protocols of Groups I, II, III, IV, V, and VI. (b) Tumor volumes on day 14 after re-challenge with B16F1 melanoma. All data are presented as mean ± standard deviation. Tumor volumes of Groups III and IV were found to be significantly reduced compared with those of the control group ( and , resp.) and Group VI ( and , resp.) by the Scheffé test. (c) Kaplan-Meier survival curves over a period of 60 days after re-challenge with B16F1. The survival rate of Group III was significantly prolonged compared with those of the control group () and Group VI (). The survival rate of Group IV was significantly prolonged compared with that of the control group (), Group I (), Group II (), and Group VI (). One of the eight mice in Group III and three of the nine mice in Group IV were protected against re-challenge with B16F1 melanoma cells.
Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.